Medvedev IN
The combination of arterial hypertension and metabolic syndrome causes a whole complex of disorders in the patients' body, contributing to the risk of developing thrombosis in them. In this regard, it is very important to develop a comprehensive therapy for this patient population, which positively influences the activity of platelets, which is an important factor in the formation of thrombophilia in them. The aim of the work is to establish the intensity of the dynamics of platelet aggregation ability and the state of functional capabilities, the individual mechanisms of their determining in patients with arterial hypertension of the third degree in the metabolic syndrome. 24 patients with arterial hypertension of the 3rd degree, risk 4, including 10 men and 14 women of mature age, were under observation. The control group consisted of 25 clinically healthy people of similar age. The surplus platelet activity observed in the in vitro and in vivo patients is based on an increase in the adhesive and aggregation activity of platelets with a weakening of their ability to disaggregate, largely due to an imbalance in their blood pressure and anti-aggregational compounds. The complex therapy, including amlodipine, valsartan, pioglitazone, hypocaloric diet and dose physical exercise, provided patients with arterial hypertension 3 degrees with metabolic syndrome after 4 months. Stable normalization of initially high platelet activity, significantly reducing their risk of developing thrombosis, despite the non-strict compliance with the non-drug component of treatment after 16 weeks of treatment.
English 
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi